查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371890

到 2030 年抗菌素抗藥性診斷市場預測：按病原體、技術、最終用戶和地區進行的全球分析

Antimicrobial Resistance Diagnostic Market Forecasts to 2030 - Global Analysis By Pathogen, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球抗菌素抗藥性診斷市場規模為 47.6 億美元，預計到 2030 年將達到 95.8 億美元，預測期內年複合成長率為 10.5%。

用於發現和證明微生物中抗菌素抗藥性（AMR）存在的診斷測試和設備市場被稱為「抗菌素抗藥性診斷市場」。抗生素抗藥性是全世界主要的公共衛生問題，因為微生物（包括細菌、病毒、真菌和寄生蟲）發展出抵抗抗生素作用的能力，導致治療感染疾病的效果降低或消失。

根據美國藥典公約，AMR 每年導致全球約 70 萬人死亡。此外，如果微生物感染疾病的診斷和治療管理不當，到2050年每年這一數字可能會達到1000萬人。

配合措施和提高認知

隨著醫療保健專業人員、立法者和公眾對抗生素抗藥性影響的了解不斷加深，解決這一問題的配合措施也加大了。此外，政府、組織和法規發起了鼓勵負責任地使用抗生素的運動，並開始創建和接受對抗抗藥性的診斷工具。

昂貴的診斷和有限的報銷政策

一些最先進的抗菌素抗藥性診斷測試價格昂貴，而且其取得和使用可能受到限制，特別是在資源匱乏的地區。診斷測試的高價格可能會阻礙市場擴張，特別是在醫療資源匱乏的地區。然而，根據地區和醫療保健系統，抗菌素抗藥性診斷可能會根據不同的保單得到承保和報銷。特定測試的付款不足或缺乏保險可能會阻礙其普及和市場擴張。

技術開發、指南和法規遵從性

分子診斷和次世代定序等領域診斷技術的進步正在提高抗生素抗藥性測試的能力。這些創新使抗藥性標記物能夠更快、更準確地被檢測到，從而使醫療專業人員能夠確定有效的治療方法。此外，法規機構和醫療保健組織已經認知到抗生素抗藥性的重要性，並發布了建議和指南來促進抗生素的使用。這些法規促進了診斷技術的普及，同時支持市場擴張所需的法規環境。

基礎設施和專業知識不足，法規程序複雜

缺乏抗菌藥物抗藥性測試的知識可能會阻止某些地區充分發揮其潛力。醫療保健基礎設施不足和缺乏檢測空間也可能阻礙現代診斷技術的使用並限制市場擴張。然而，要獲得法規核准新的抗生素抗藥性診斷測試可能既耗時又困難。新診斷方法的推出受到嚴格法規的阻礙，這往往會延遲產品的發布。

COVID-19 的影響：

由於 COVID-19 大流行，醫療保健的優先事項發生了巨大變化，重點是管理和遏制病毒的傳播。資源被用於 COVID-19 檢測和治療，包括實驗室能力和人員。這種資源的重新分配可能暫時阻礙了對該領域抗菌素抗藥性診斷和研究的關注。由於 COVID-19 患者可能繼發細菌感染，因此 COVID-19 大流行導致抗生素使用增加。

預計耐甲氧西林金黃色葡萄球菌在預測期內將達到最高水平

在預測期內，抗甲氧西林金黃色葡萄球菌佔據最大佔有率。此細分市場成長的主要原因是醫院環境中耐甲氧西林金黃色葡萄球菌（MRSA）的患病不斷增加。例如，美國疾病管制與預防中心 (CDC) 報告稱，鼻子裡有金黃色葡萄球菌的人中約有 100 人患有 MRSA。這一比例約為人口的33%。此外，影響該細分市場成長的另一個因素是越來越多的法規核准用於識別 MRSA 的診斷測試。

預計醫院領域在預測期內的年複合成長率最高。

由於醫院感染率上升、AMR 感染率高導致住院人數急劇增加、住院時間更長、更容易獲得尖端診斷技術、負擔能力以及醫療覆蓋範圍的改善，醫院領域預計將出現下滑。在此期間實現盈利成長。此外，MRSA、CDI、DRSP等病原體感染還會引起肺炎、敗血症、血流感染、手術部位感染等。因此，醫院中以病原體為重點的疾病爆發也促進了這一領域的成長。

比例最高的地區：

由於抗微生物藥物抗藥性發展的高風險、政府對抗微生物藥物抗藥性的法規以及先進的醫療基礎設施，北美在預測期內佔據最大佔有率。此外，主要市場參與企業的存在和策略性舉措預計將推動未來年度的區域擴張。

複合年複合成長率最高的地區：

預計亞太地區在預測期內將出現最快的擴張。抗生素抗藥性的高頻率、對負擔得起的診斷解決方案的需求不斷增加以及開拓的市場潛力的存在正在促進該地區的成長。此外，預計該地區的擴張將受到大量目標人口、不斷成長的老年人口以及眾多政府資助的宣傳活動的推動。此外，與創建改進的診斷解決方案相關的研發工作的成長預計將支持該地區的擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球抗菌素抗藥性診斷市場：依病原體分類

  • 抗藥性鏈球菌
  • 抗藥性肺炎鏈球菌 (DRSP)
  • 抗甲氧西林金黃色葡萄球菌
  • 艱難梭菌 (CD)
  • 抗藥性淋病 (DRNG)
  • 抗藥性沙門氏菌 (DRNTS)
  • 其他病原體

第6章 全球抗菌素抗藥性診斷市場：依技術分類

  • 免疫檢測
  • 微生物培養
  • 質譜
  • 快速且即時護理
  • 其他技術

第7章 全球抗菌素抗藥性診斷市場：依最終用戶分類

  • 製藥和生物技術公司
  • 診斷實驗室
  • 醫院
  • 其他最終用戶

第8章 全球抗菌素抗藥性診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Molsid
  • OpGen
  • Vela Diagnostics
  • Visby Medical, Inc.
Product Code: SMRC23947

According to Stratistics MRC, the Global Antimicrobial Resistance Diagnostic Market is accounted for $4.76 billion in 2023 and is expected to reach $9.58 billion by 2030 growing at a CAGR of 10.5% during the forecast period. The market for diagnostic tests and instruments used to find and establish the presence of antimicrobial resistance (AMR) in microorganisms is referred to as the "antimicrobial resistance diagnostic market." As a result of the development of the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to withstand the effects of antimicrobial medications, which reduces or eliminates their effectiveness in treating infections, antimicrobial resistance is a major public health concern worldwide.

According to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.

Market Dynamics:

Driver:

Increasing initiatives and awareness

Increased initiatives aimed at combating the problem were made possible by the growing knowledge of the effects of antibiotic resistance among healthcare professionals, legislators, and the general public. Furthermore, governments, organizations, and regulatory authorities have started campaigns to encourage the responsible use of antibiotics as well as the creation and acceptance of diagnostic tools to combat resistance.

Restraint:

Expensive diagnostic procedures and policies for limited reimbursement

Some cutting-edge antimicrobial resistance diagnostic tests can be expensive, which restricts access to and use of them, particularly in places with low resources. The high price of diagnostic tests may be an obstacle to market expansion, especially in areas with constrained healthcare resources. However, antimicrobial resistance diagnostics may be covered and reimbursed under different policies, depending on the region and healthcare system. Their uptake and market expansion may be hampered by inadequate payment or a lack of insurance coverage for certain tests.

Opportunity:

Technological developments and guidelines and support for regulations

Diagnostic technology advancements in areas like molecular diagnostics and next-generation sequencing have improved the capability of tests for antibiotic resistance. These innovations allow for the quicker and more precise detection of resistance markers, empowering medical professionals to determine effective treatments. Additionally, the importance of antibiotic resistance has been acknowledged by regulatory bodies and healthcare organizations, which have released recommendations and guidelines to promote their usage. These regulations support the regulatory environment needed for market expansion while facilitating the uptake of diagnostics.

Threat:

Inadequate infrastructure and expertise and complex regulatory procedures

Antimicrobial resistance tests may not be used to their full potential in some areas due to a lack of knowledge about them. Inadequate healthcare infrastructure and a lack of laboratory space might also prevent the use of modern diagnostics and restrain market expansion. However, it might take a while and be difficult to get regulatory approval for novel diagnostic tests for antibiotic resistance. The introduction of novel diagnostics might be hampered by strict regulatory regulations, which can often delay the launch of products.

COVID-19 Impact:

Priorities in healthcare have dramatically changed as a result of the COVID-19 pandemic to focus on managing and containing the virus's spread. Resources have been redirected toward COVID-19 testing and treatment, including laboratory capacity and manpower. The concentration on antimicrobial resistance diagnostics and research efforts in this area may have been momentarily hampered by this resource relocation. Due to the possibility of secondary bacterial infections in COVID-19 patients, the COVID-19 pandemic has resulted in an increase in the use of antibiotics.

The methicillin resistant staphylococcus aureus segment is expected to be the largest during the forecast period

Methicillin Resistant Staphylococcus Aureus segment commanded the largest share over the forecast period. The main cause of the segment's growth is the rising prevalence of MRSA in hospital settings. For instance, the CDC reports that approximately two in every 100 of those with S. aureus on their noses develop MRSA. This percentage of the population is roughly 33%. Moreover, another element influencing the segment's growth is the rise in regulatory approvals for diagnostic tests for identifying MRSA.

The hospitals segment is expected to have the highest CAGR during the forecast period

Because of the rising rate of hospital-acquired infections, the surge in hospitalizations caused by the high rate of AMR infections, prolonged hospital stays, expanding access to cutting-edge diagnostic technologies, affordability, and better healthcare coverage, the hospital segment is predicted to grow profitably over the forecast period. Additionally, pathogenic infections, including MRSA, CDI, and DRSP, can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused illnesses in hospitals also contributes to segment growth.

Region with largest share:

Due to the high risk of developing AMR, the presence of supportive government AMR regulations, and the region's advanced healthcare infrastructure, North America held the largest percentage over the predicted period. Furthermore, it is anticipated that regional expansion will be fueled in the upcoming years by the existence of major market participants and the strategic initiatives.

Region with highest CAGR:

During the forecast period, Asia-Pacific is expected to experience the most rapid expansion. A high frequency of antibiotic resistance, an increase in the demand for affordable diagnostic solutions, and the presence of unexplored market potential all contribute to the region's growth. Additionally, the region's expansion is also anticipated to be aided by the region's sizable, targeted population, growing geriatric population, and a number of government-sponsored awareness campaigns. Additionally, it is anticipated that growth in R&D efforts connected to the creation of improved diagnostic solutions will support region expansion.

Key players in the market:

Some of the key players in Antimicrobial Resistance Diagnostic market include: Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux , Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Molsid , OpGen, Vela Diagnostics and Visby Medical, Inc..

Key Developments:

In November 2022, Danaher Corporation came into partnership with Duke University, a research University. Under this partnership, Danaher Corporation aimed to shape Danaher Beacon for the development of Gene Therapy Innovation.

In August 2022, Becton, Dickinson, and Company entered into collaboration with Accelerate Diagnostics, Inc., a developer of rapid in-vitro diagnostics in microbiology. This Collaboration would enable the former company to help clinicians treat patients in a Constructive and organized way resulting in a decrease in costs in healthcare and helping restrict the stretch of antimicrobial resistance.

Pathogens Covered:

  • Drug Resistant Streptococcus
  • Drug Resistant Streptococcus Pneumoniae (DRSP)
  • Methicillin Resistant Staphylococcus Aureus
  • Clostridium Difficile (CD)
  • Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • Drug Resistant Salmonella (DRNTS)
  • Other Pathogens

Technologies Covered:

  • Immunoassay
  • Microbiology Culture
  • Mass Spectrometry
  • Rapid & Point of Care
  • Other Technologies

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antimicrobial Resistance Diagnostic Market, By Pathogen

  • 5.1 Introduction
  • 5.2 Drug Resistant Streptococcus
  • 5.3 Drug Resistant Streptococcus Pneumoniae (DRSP)
  • 5.4 Methicillin Resistant Staphylococcus Aureus
  • 5.5 Clostridium Difficile (CD)
  • 5.6 Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • 5.7 Drug Resistant Salmonella (DRNTS)
  • 5.8 Other Pathogens

6 Global Antimicrobial Resistance Diagnostic Market, By Technology

  • 6.1 Introduction
  • 6.2 Immunoassay
  • 6.3 Microbiology Culture
  • 6.4 Mass Spectrometry
  • 6.5 Rapid & Point of Care
  • 6.6 Other Technologies

7 Global Antimicrobial Resistance Diagnostic Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical & Biotechnology Companies
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Antimicrobial Resistance Diagnostic Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Accelerate Diagnostics, Inc.
  • 10.3 Becton, Dickinson and Company
  • 10.4 Biomerieux
  • 10.5 Danaher Corporation
  • 10.6 F. Hoffmann-La Roche Ltd.
  • 10.7 Hologic, Inc.
  • 10.8 Molsid
  • 10.9 OpGen
  • 10.10 Vela Diagnostics
  • 10.11 Visby Medical, Inc.

List of Tables

  • Table 1 Global Antimicrobial Resistance Diagnostic Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 3 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 4 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 5 Global Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 6 Global Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 7 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 8 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 9 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 10 Global Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 11 Global Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 12 Global Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 13 Global Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 14 Global Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 15 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 16 Global Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 17 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 18 Global Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 19 Global Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 20 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 21 North America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 23 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 24 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 25 North America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 26 North America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 27 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 28 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 29 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 30 North America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 32 North America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 33 North America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 34 North America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 35 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 36 North America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 38 North America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 39 North America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 41 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 43 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 44 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 45 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 46 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 47 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 48 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 49 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 50 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 51 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 52 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 53 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 54 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 55 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 56 Europe Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 57 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 58 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 59 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 60 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 63 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 64 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 65 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 66 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 67 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 68 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 69 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 70 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 71 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 72 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 73 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 74 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 75 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 76 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 77 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 78 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 79 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 80 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 South America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 83 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 84 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 85 South America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 86 South America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 87 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 88 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 89 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 90 South America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 91 South America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 92 South America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 93 South America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 94 South America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 95 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 96 South America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 98 South America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 99 South America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 100 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 103 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 104 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 105 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 106 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 108 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 109 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 110 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 111 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 112 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 113 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 114 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 115 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 116 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 118 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 119 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 120 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)